Wellcome Leap has announced that a multidisciplinary team led by the Finnish quantum software company Algorithmiq is the winner of the $2 million Quantum for Bio (Q4Bio) Supported Challenge prize. The 30-month, $50 million initiative was designed to accelerate the development of quantum algorithms specifically for human health. While today’s quantum computers are not yet capable of outperforming classical machines in biology (a milestone known as “quantum advantage”), the prize recognizes the first experimental realization of an end-to-end quantum-classical workflow for a complex therapeutic, providing a scalable roadmap for future health breakthroughs. The winning project, conducted in collaboration with IBM and the Cleveland Clinic, focused on photodynamic therapy (PDT)—a cancer treatment that utilizes light-activated drugs (photosensitizers) to destroy tumors with minimal toxicity to surrounding tissue. Using an IBM Quantum System One located at the Cleveland Clinic, the team successfully simulated the excited-state properties of a photosensitizer drug. This required replicating the complex interaction between photons and electrons, a task specifically suited for quantum computation. The demonstration utilized 100 qubits and achieved circuit depths between 1,000 and 10,000 gates, meeting the rigorous technical criteria established by Wellcome Leap. Beyond the winning entry, the Q4Bio program whittled dozens of applicants down to six finalists, each of whom made significant contributions to the life sciences computational stack. The University of Oxford and the Sanger Institute achieved a technical first by encoding a viral genome (Hepatitis-D) onto quantum hardware, while a team led by Infleqtion and the University of Chicago utilized hybrid quantum-classical optimization to discover novel multimodal cancer biomarkers. Other finalists, including teams from Stanford and the University of Nottingham, explored biochemical reactions like ATP hydrolysis and the design of covalent inhibitors for untreatable genetic disorders. One of the program’s most significant outcomes was the shift from theoretical exploration to “utility-scale” hardware validation.